Mirum Pharmaceuticals (MIRM) Interest Expenses (2020 - 2026)

Mirum Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $26.7 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 79.65% year-over-year to $26.7 million; the TTM figure through Mar 2026 stood at $26.7 million (down 79.65% YoY), while the FY2025 annual figure was $480.0 million, up 105.86% from the prior year.
• Interest Expenses for Q1 2026 stood at $26.7 million, up from -$3.7 million in the prior quarter.
• The five-year high for Interest Expenses was $293.7 million in Q2 2025, with the low at -$10.5 million in Q4 2023.
• The 5-year median for Interest Expenses is $27.3 million (2022), against an average of $69.9 million.
• Peak annual rise in Interest Expenses reached 3913.88% in 2023, while the deepest fall reached 338.94% in 2023.
• Mirum Pharmaceuticals' Interest Expenses stood at $4.4 million in 2022, then tumbled by 338.94% to -$10.5 million in 2023, then jumped by 160.45% to $6.3 million in 2024, then tumbled by 159.05% to -$3.7 million in 2025, then jumped by 815.98% to $26.7 million in 2026.
• Business Quant data shows MIRM's Interest Expenses at $26.7 million in Q1 2026, -$3.7 million in Q4 2025, and $131.4 million in Q3 2025.